NRIX vs REGN · rev $54.5M vs P/E 14, rev $14.34B
Nurix Therapeutics Inc (NRIX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
NRIX currently screens at market cap $1.77B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the NRIX and REGN stock pages for the full models.
Not investment advice.